The market for CBD infused products is just starting to take off. Major players in the cannabis industry such as Aurora Cannabis, Canopy Growth and Tilray, to name just a few, are already selling oils and tinctures derived from Cannabis CBD and with the launch of Cannabis 2.0 CBD infused products will soon be available. So how can InnoCan Pharma (first introduced to the CIG Community here) a small startup company out of Israel walk confidently amongst the giants of the cannabis industry?
To start with, InnoCan Pharma is led by a management team with an enviable pedigree. The founders of InnoCan have extensive experience and commercially successful records in the pharmaceutical and technology sectors in Israel and globally.
- Ron Mayron – Executive Chairman. Former CEO of Teva Israel & Africa
- Yoram Druker – VP Business Development. Successful entrepreneur and expert in the establishment of start-ups.
- Iris Bincovich – CEO. Extensive experience and proven track record developing global business strategies to open and penetrate new markets.
- Nir Avram – CTO. More than 30 years of experience and holder of several patents.
To learn more about this multidisciplinary team and their advisory board, go to
First Mover Advantage
InnoCan brings the strict discipline of Pharmacology to the rapidly growing CBD industry, incorporating synergistic ingredients with CBD to enhance the potency and efficacy of current products for better results.
Mayron believes they are one of the few companies in such an advanced stage of developing this approach.
Their initial offerings will be over-the-counter (OTC) topical treatment for psoriasis and pain, combining proven drugs with CBD from industrial Hemp oil. But in my opinion, the real game changer for InnoCan Pharma, is the development of a breakthrough technology platform to deliver cannabinoids by injection of hydrogel-cannabinoid-loaded liposomes into the blood stream or to a specific body part.
The liposome platform injection technology seeks to address the limitations of oral ingestion of CBD; particularly the loss of bioavailability and the otherwise lack of targeted internal delivery.Iris Bincovich, CEO
Although there are about 15 FDA approved liposomal drugs currently on the market, as far as I know, InnoCann have a good chance to be the first to offer this application using CBD and or other cannabinoids. Iris Bincovich, InnoCan’s CEO, noted, ‘The liposome platform injection technology seeks to address the limitations of oral ingestion of CBD; particularly the loss of bioavailability and the otherwise lack of targeted internal delivery.’
This is been developed by the Hebrew university at Jerusalem, Israel , InnoCan’s agreement with Yissum, the commercial arm of the Hebrew University provides InnoCan with an exclusive option for a worldwide license agreement with respect to the results of the research under the agreement. Yissum has filed a provisional patent covering this unique platform, which will give InnoCan a first mover advantage in this method of CBD platform technology and a serious competitive advantage in the licensing and sale of this technology to pharmaceutical companies.
Market Entry Strategy
InnoCan may be a small startup pharma company at this point, but its prospects are anything but small. The company expects to leverage a rapid US Food and Drug Administration OTC drug process to shorten the regulatory approval process. Their strategy is either to license the formulations to strategic partners locally, regionally and globally and/or to collaborate with local distributors.
Initial product offerings will be CBD-integrated topical applications to treat Psoriasis and relief of muscle pain and mild arthritis pain. The decision to start with these two products is based on the fact that the use of CBD in assisting the treatment of Psoriasis and muscle and joint pain is already widely researched and accepted. This is a multibillion-dollar market making it a good entry point to introduce the InnoCan brand.
InnoCan Pharma’s operations will focus on three market segments:
- Research, development, marketing, distribution and sales of InnoCan-branded OTC pharmaceutical products sold through distributors.
- Research and development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales.
- Research and development of non-pharmaceutical CBD infused products for third parties in exchange for fees and/or royalties.
On September 25th InnoCann Pharma announced the closing of its IPO and listing on the Canadian Securities Exchange (CSE). The company raised CDN $1.1 million through the sale of 6,111,112 units (the “Units”) at a price of CDN $0.18 per Unit. Each Unit consists of one common share in the capital of the Company (each, a “Common Share”) and one-half of one Common Share purchase warrant (each whole Common Share purchase warrant, a “Unit Warrant”). Each Unit Warrant entitles the holder thereof to acquire one Common Share at an exercise price of CDN $0.30 for a period of 24 months following September 25, 2019, subject to acceleration in certain cases. The Warrants will not be listed for trading.
Shares opened for trading on the CSE (INNO) at $.25 CDN and as of the time of this writing share price has increased 20% to $.30 CDN.
Disclaimer: All posts made on this website are provided for information purposes only. None of the information here is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, Company, or fund. Before making an investment decision, you should seek the advice of a qualified and registered securities professional. The author is paid to share this information and may or may not own shares in the company.
Disclosure: I am long on Aurora Cannabis. I have no positions in any other stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Cannabis Investment Group). I have no business relationship with any company whose stock is mentioned in this article.